Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Oliver Sartor MD

Oliver Sartor MD

Director of the Radiopharmaceutical Trials, Chief of the Genitourinary Cancer Malignancy Group, Mayo Clinic, Rochester, Minnesota

Dr. Oliver Sartor is a medical oncologist in the Division of Medical Oncology in the Department of Oncology at the Mayo Clinic in Rochester, Minnesota. He serves as Chair of the Genitourinary Cancer Disease Group and the Director of Radiopharmaceutical Clinical Trials for the Mayo Clinic Comprehensive Cancer Center.

Dr. Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, led or co-led multiple national and international clinical studies, including four phase III studies pivotal for FDA approval of drugs for advanced prostate cancer (Quadramet, Xofigo, Pluvicto, and Jevtana). He has lectured widely, and, at last count, has given invited lectures in 33 countries. He is the Medical Oncology Chair of the Genitourinary Cancer Committee of NRG, a national cancer research group.

Disclosures

  • Consultant: Advanced Accelerator Applications (AAA); Astellas; AstraZeneca; Bayer; Blue Earth Diagnostics; Bavarian Nordic; Bristol Myers Squibb; Clarity Pharmaceuticals; Clovis; Constellation; Dendreon; EMD Serono; Fusion; Isotopen Technologien Muenchen; Janssen; Merck; Myovant; Myriad; Noria Therapeutics; Novartis; Noxopharm; Progenics; POINT Biopharma; Pfizer; Sanofi; Teneobio; Telix; Theragnostics
  • Research funding: Advanced Accelerator Applications; Amgen; AstraZeneca; Bayer; Constellation; Endocyte; Invitae; Janssen; Lantheus; Merck; Progenics; Teneobio

Recent Contributions to PracticeUpdate:

  1. ESMO 2024: Recommendations From Dr. Oliver Sartor for Prostate Cancer
  2. Short-Course vs No Androgen Deprivation Therapy Added to Postoperative Radiotherapy for Prostate Cancer
  3. Long-Course vs Short-Course Androgen Deprivation Therapy Plus Postoperative Radiotherapy for Prostate Cancer
  4. ASCO 2024: Abstract Recommendations From Dr. Oliver Sartor for Prostate Cancer
  5. Intensification of Androgen Blockade in Men With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer
  6. 2023 Top Story in Prostate Cancer: PARP Inhibition Moves Forward
  7. Digital Pathology–Based Multimodal AI-Derived Model in Localized Metastatic Prostate Cancer
  8. Refining Risk Stratification in Patients Undergoing Radiotherapy and Long-Term ADT for High-Risk/Locally Advanced Prostate Cancer
  9. Pembrolizumab Plus Enzalutamide and ADT for Patient With mHSPC
  10. AMG 509 (Xaluritamig) in Patients With mCRPC

Most Read This Week

Recently Updated